NCT04246866View on ClinicalTrials.gov

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2020

Conditions
Dry Age-related Macular DegenerationGeographic AtrophyMacular DegenerationRetinal DiseaseRetinal Degeneration
Interventions
BIOLOGICAL

GEM103

GEM103

Trial Locations (12)

28803

Western Carolina Retinal Associates, Asheville

30909

Southeast Retina Center, Augusta

46290

Midwest Eye Institute, Indianapolis

63017

Pepose Vision Institute, Chesterfield

85020

Associated Retina Consultants, Phoenix

85053

Retinal Consultants of Arizona, Phoenix

89502

Sierra Eye Associates, Reno

90211

Retina Vitreous Associates, Beverly Hills

93036

California Retina Consultants, Oxnard

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

Sponsors
All Listed Sponsors
lead

Gemini Therapeutics, Inc.

INDUSTRY